AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05465044 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thrice-Weekly Hemodialysis
Description: 50% of the eligible participants will be assigned to outright thrice-weekly hemodialysis, which will be continuation of the initial thrice-weekly schedule during the run-in period, without the option to switch to less frequent dialysis schedule representing the standard of care.
Study NCT06072612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SV-BR-1-GM
Description: SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity
Study NCT05134727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055
Description: Healthy participants will receive AZD5055
Study NCT06072612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
Study NCT06072612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon infiltration of the inoculation site
Description: Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
Study NCT06072612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
Study NCT06072612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of Physician's Choice
Description: Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
Study NCT06098599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin hydrochloride liposome injection
Description: Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.
Study NCT06098599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride liposome injection
Description: Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.
Study NCT06527287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Ankle Training for Instablity to Optimize Neuromusculoskeletal outcomes (NATION)
Description: The NATION rehabilitation protocol will serve as the true intervention group. NATION is a 6-week evidence-based chronic ankle instability (CAI) rehabilitation protocol that incorporates neurocognitive exercises. Participants will complete up to 18 unsupervised home sessions and up to 12 supervised sessions. Treatment volume and exercises may vary based on participant progress and study team member guidance.
Study NCT06527287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-Based
Description: The Evidence-Based rehabilitation protocol will serve as the active comparator group. The Evidence-Based protocol will be similar to the intervention (i.e., NATION protocol), but the exercises will exclude the neurocognitive tasks. Participants assigned to the Evidence-Based protocol will complete up to 18 unsupervised home sessions and up to 12 supervised sessions over the course of 6-weeks. Treatment volume and exercises may vary based on participant progress.
Study NCT04280211 — intervention group
Intervention type: OTHER
Intervention: Respiratory Assessment
Description: Spirometric measurement
Study NCT04280211 — intervention group
Intervention type: OTHER
Intervention: Vestibular Assessment
Description: Assessment of peripheral vestibular dysfunction, angular vestibule ocular reflex, vestibular dysfunction
Study NCT04280211 — intervention group
Intervention type: OTHER
Intervention: Balance Assessment
Description: Postural stability
Study NCT05134727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Healthy participants will receive placebo
Study NCT05573646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: Participants will receive a one-hour online group-based dual-task training session twice a week for 12 weeks, giving a total intervention time of 24 hours. A co-design approach will be adopted to develop the training components in the dual-tasks. For the cognitive training component, arithmetic operation, verbal fluency, and upper limb/ finger movements are included. For the physical training component, we select chair-based exercises are included. A group-based training mode led by a facilitator will be adopted. During the session, participants will be asked to turn on their camera so that they can see and interact with each other. They will also have their audio on as they will have to participate in the cognitive tasks by voicing out their answers.
Study NCT05573646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Attention Control
Description: Participants will receive eight one-hour online group-based interactive education on health topics other than exercise and cognitive health.
Study NCT06564155 — intervention group
Intervention type: DEVICE
Intervention: carotid duplex
Description: measure Carotid intima media thickness
Study NCT06459128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limbic Care
Description: Limbic Care is an AI-enabled smartphone application that delivers cognitive behavioral therapy (CBT) interventions and psychoeducation to users via an interactive, conversational interface using AI. Participants can choose from three courses (sleep, worry, and low mood) that sets the type of content they will see in the app. For each course, different interventions and psychoeducation material will appear in the to do list section of the app on a fixed schedule. The app also allows users to engage in open-ended conversation with the AI, which serves as an non-interventional, empathetic listener.
Study NCT06459128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Workbook
Description: The digital workbook in PDF format will be provided to participants via the Internet. Participants can choose from three workbooks that each focus on a different topic: sleep, worry, and low mood. Each workbook contains psychoeducation material and CBT intervention worksheets, consisting of text, images, and response boxes to write in (if printed out).
Study NCT05822024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Pupils' Physical Literacy Intervention
Description: The physical literacy intervention 3PL is based on activities, games, and modifications of the physical education classes to target and enhance pupils' physical literacy.
Study NCT05341583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
Study NCT05341583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
Study NCT04734236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: New technique vs Xpert
Description: New technique vs Xpert
Study NCT04734236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: New technique vs Xpert
Description: New technique vs Xpert
Study NCT05350358 — intervention group
Intervention type: DEVICE
Intervention: LeMaitre Cardial Dialine II
Description: Surgical treatment for the replacement or bypass with LeMaitre Cardial Dialine II
Study NCT04671329 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Affirm Contrast Biopsy procedure
Description: Contrast Enhanced Digital Mammography (CEDM) is an extension of the existing indication for diagnostic mammography with the Selenia Dimensions system and 3Dimensions system. Biopsy targeting can be done on captured contrast enhanced images (scout and stereo pair). The CEDM application shall enable contrast enhanced breast imaging using a dual energy technique. This imaging technique can be used as an adjunct following mammography and/or ultrasound exams to localize a known or suspected lesion. Affirm Contrast Biopsy is intended for patients recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities.
Study NCT05943158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: myoinositol and folic acid
Description: The pregnant women were given myoinositol+folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
Study NCT05943158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: The pregnant women were given only folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
Study NCT05903820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol patch
Description: Transdermal patch of estradiol
Study NCT06358924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potassium nitrate with fluoride
Description: Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of the desensitizing agent recommended by the manufacturer (After Whitening Mousse), once for 10 minutes.
Study NCT06358924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide-amorphous calcium phosphate with fluoride
Description: Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Mi Paste Plus once for 3 minutes.
Study NCT06358924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite with fluoride
Description: Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Hydroxyapatite and Fluoride (ReminPro) once for 3 minutes.
Study NCT06358924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAMAM-carboxylic acid dendrimer
Description: Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of PAMAM once for 30 minutes.
Study NCT06167447 — intervention group
Intervention type: OTHER
Intervention: questionnaire and examination
Description: Demographic data of all participants, height, weight, body mass index, occupation, marriage status, education level, comorbidities, medications used, duration of illness and subtype will be recorded by the researcher. Questionnaires to be filled by patients. On the same day, the musculoskeletal system and neurological examination of the participants will be evaluated by the researcher.
Study NCT06312098 — intervention group
Intervention type: OTHER
Intervention: remote ischemic preconditioning (RIPC)
Description: After induction of anesthesia, the paired RIPC group took the RIPC intervention on the upper arm in the lateral position. The RIPC intervention was applied using a manual cuff inflator, which consisted of three cycles of 5-min inflation of the blood pressure cuff (to 250 mmHg, or to 50 mmHg higher than the preoperative SBP), followed by 5-min deflation of the cuff. In the no-RIPC group, a blood pressure cuff was also applied on the upper arm but was not inflated.
Study NCT05242614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Hybrid Mindfulness-based Dementia caregiving program (MBDCP)
Description: The hybrid MBDCP includes 6 weekly 90-minute group-based sessions delivered through a face-to-face (1st, 2nd, and 6th sessions) and online approach (3rd, 4th, and 5th sessions). The online session is designed for self-directed learning. The MBDCP includes different mindfulness practices (e.g., mindful eating, body scanning, and mindful walking), psychoeducation on caregiving, and group sharing, aimed at helping caregivers to develop mindfulness skills through the formal and informal practice of mindfulness, and to integrate these skills into their everyday life. The duration of each session is 90 minutes. Th MBDCP will be delivered by a qualified mindfulness therapist. In the MBDCP's online sessions, the caregivers will watch a teaching video (e.g., a video demonstrating mindfulness practices) through a website.
Study NCT05242614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation educational program
Description: This program serves as a control for the social effects of the MBDCP. The brief education program consists of 6 weekly 90-minutes group sessions in which the sessions (1st, 2nd, and 6th) and (3rd 4th 5th) will be delivered through the face-to-face and online approach respectively, with the similar group size of the MBDCP. The education contents include caregiving skills, education on mood, and group sharing. The program will be led by a nurse.
Study NCT06425393 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urea beath test (UBT)
Description: H. pylori infection will be tested using a 13C-urea breath test Kit for all enrolled family members, following the manufacturer's instructions. The sensitivity and specificity of the assay are both over 95%, according to the manufacturer's introduction.
Study NCT04944823 — intervention group
Intervention type: OTHER
Intervention: Clinical follow-up for 24 months
Description: Sampling and clinical follow-up for 24 months
Study NCT04897048 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Incremental exercise test (IET)
Description: Incremental cardio pulmonary exercise test until exhaustion
Study NCT04897048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incremental exercise test (IET)
Description: Incremental cardio pulmonary exercise test until exhaustion
Study NCT04897048 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Constant work rate exercise test (CWRET)
Description: constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion
Study NCT04897048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Constant work rate exercise test (CWRET)
Description: constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion
Study NCT06533709 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radio-score
Description: A score based on the LASSO regression model predicting the R0 resection of the primary debulking surgery of advanced ovarian cancer.
Study NCT06533774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audéo Lumity 90-R
Description: This study will be using the Audeo L90-R devices, which are programmed by the hearing care professional (HCP) using Target fitting software version 8.1.
Study NCT05903820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Description: Transdermal patch of estradiol
Study NCT05903820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Oral progesterone capsules 100mg/day
Study NCT06071039 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 3D spacer Fabric Based Mattress
Description: For the patients in the intervention group, the 3D spacer fabric-based mattress was used instead of the operating room theater mattress. The pressure level of the patients was monitored throughout the surgery.
Study NCT04988165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Description: It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.
Study NCT04353297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG-based BCI system for (hand) Motor Imagery training
Description: The Promotoer is an all-in-one BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback (EEG and EMG activity monitoring) and screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. As such, this software allows the therapists to create an artificial reproduction of a given patient's hand/forearm by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hand/forearm. Training consists of the MI tasks only of the affected hand, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
Study NCT04353297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Imagery training
Description: Training consists of MI tasks only of the affected hand, grasping or finger extension in separate runs. MI training will be delivered without BCI support (ie., the Promotoer system will not provide real-time feedback of MI performance; hand/forearm visual representation will remain standstill) with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
Study NCT05485571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: derma pen
Description: Group 1: Taking aseptic condition, 15 Patients were subjected to therapy with microneedling, patient will take session weekly for 12 weeks.~Group 2: Taking aseptic condition, 15 patients were subjected to combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks
Study NCT05903820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Oral progesterone capsules 100mg/day
Study NCT06364046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug-eluting beads bronchial arterial chemoembolization
Description: Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres are loaded with irinotecan. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is irinotecan 80mg/ m2. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days.
Study NCT06364046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Programmed cell death protein 1 inhibitor fixation was treated with serplulimab (Fuhong Hanlin Co., LTD.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
Study NCT06364046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serplulimab
Description: Programmed cell death protein 1 inhibitor fixation was treated with serplulimab (Fuhong Hanlin Co., LTD.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
Study NCT06364046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous chemotherapy
Description: Intravenous chemotherapy with irinotecan 65mg/m2 on day 1 and day 8, given once every 21 days
Study NCT05937022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Transcranial Direct Current Stimulation (tDCS)
Description: This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to one of the two experimental groups will receive 20 minutes of active stimulation with a 2mA intensity over the corresponding brain regions.
Study NCT05937022 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to the sham control group will receive 30 seconds of active stimulation over brain regions identical to either the left DLPFC or the right VLPFC experimental tDCS group.
Study NCT04598282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prokera Slim
Description: Placement of an Adjunctive Cryopreserved Amniotic Membrane Treatment.